JAMP-Pregabalin: One lot recalled as some bottles may contain 150 mg capsules
Is your product affected? Check the DIN and lot number on your package against the list in Health Canada's official notice.
See affected DINs and lot numbers on Health Canada ↗Why it was recalled
Product safety
What you should do
- Check your medication bottle to ensure it only contains 50 mg capsules.
- The 50 mg capsule is white with “PG” and “50” printed on it in black ink.
- The 150 mg capsule is white with “PG” and “150” printed on it in black ink.
- If it contains any 150 mg capsules, or if you are unsure, return it to your pharmacy immediately. Your pharmacist will check the capsules and provide you with a replacement, if needed.
- If you are unable to return your capsules to the pharmacy right away, talk to your pharmacist or doctor for further guidance.
- Seek immediate medical attention if you are experiencing symptoms of an overdose (e.g., confusion, agitation, restlessness and seizures).
- Do not stop taking pregabalin without first speaking to your doctor, as stopping abruptly may result in withdrawal symptoms.
- If you have questions about this recall, contact JAMP Pharma Corp. by calling 1-866-399-9091, extension 501, or by emailing custjamp@jamppharma.com.
- Report any health product-related side effects or complaints to Health Canada.
Other Recent Recalls
PDP-DIPHENHYDRAMINE
PDP-DIPHENHYDRAMINE 25 MG and 50 MG CAPSULES: Out-of-specification (Impurity)
Type II2026-11-09
Moderate health risk
Unauthorized injectable peptide and non-peptide drugs
Health Canada warns about contaminated unauthorized injectable peptides and non-peptide drugs
2026-11-06
ANTICOAGULANT SODIUM CITRATE SOLUTION, USP
ANTICOAGULANT SODIUM CITRATE SOLUTION, USP 4g/100mL and Potential Bag Leaks
2026-11-03
Recall data is sourced from Health Canada's Recalls and Safety Alerts open dataset. MedShort.ca is an independent tracking tool and does not provide medical advice — for questions about this recall, contact the manufacturer or your pharmacist, or read the full notice linked above.